Benzinga | Dec 16, 2021 09:11AM EST

AstraZeneca Says Evusheld 'retained neutralising activity against the Omicron SARS-CoV-2 variant'

https://www.astrazeneca.com/content/astraz/media-centre/press-releases/2021/evusheld-long-acting-antibody-combination-retains-neutralising-activity-against-omicron-variant-in-independent-fda-study.html